nafamostat has been researched along with Transfusion Reaction in 4 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
Transfusion Reaction: Complications of BLOOD TRANSFUSION. Included adverse reactions are common allergic and febrile reactions; hemolytic (delayed and acute) reactions; and other non-hemolytic adverse reactions such as infections and adverse immune reactions related to immunocompatibility.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A 47-year-old male with esophageal cancer, who received 3 units of packed red cells and 20 units of platelet concentrates from 5 unrelated donors, was diagnosed as having PT-GVHD on the basis of typical clinical features, HLA typing of the patient and the responsible donor, and a mixed chimera of CD8+ lymphocytes on microsatellite DNA polymorphism analysis." | 1.30 | Treatment of post-transfusion graft-versus-host disease with nafmostat mesilate, a serine protease inhibitor. ( Hashimoto, M; Juji, T; Kohsaki, M; Okada, M; Ryo, R; Saigo, K; Tadokoro, K; Watanabe, N; Yasufuku, M, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (75.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nishimura, M | 2 |
| Akaza, T | 1 |
| Tadokoro, K | 3 |
| Juji, T | 3 |
| Ryo, R | 1 |
| Saigo, K | 1 |
| Hashimoto, M | 1 |
| Kohsaki, M | 1 |
| Yasufuku, M | 1 |
| Watanabe, N | 1 |
| Okada, M | 1 |
| Yamamura, M | 1 |
| Miyamoto, T | 1 |
| Yao, H | 1 |
4 other studies available for nafamostat and Transfusion Reaction
| Article | Year |
|---|---|
Potential usefulness of protease inhibitor and chloroquine in the treatment of transfusion-associated graft-versus-host disease.
Topics: Antigen-Presenting Cells; Antimalarials; Benzamidines; Chloroquine; Cytotoxins; Graft vs Host Diseas | 1997 |
Treatment of post-transfusion graft-versus-host disease with nafmostat mesilate, a serine protease inhibitor.
Topics: Benzamidines; Blood Donors; CD8-Positive T-Lymphocytes; DNA; Erythrocyte Transfusion; Esophageal Neo | 1999 |
Open heart surgery in a patient with autoimmune hemolytic anemia.
Topics: Aged; Anemia, Hemolytic, Autoimmune; Anti-Inflammatory Agents; Benzamidines; Betamethasone; Cardiopu | 1999 |
Treatment of post transfusion graft-versus-host disease.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Benzamidines; Drug Evaluation; Female; Graft vs Host | 2000 |